Equities

West Pharmaceutical Services Inc

West Pharmaceutical Services Inc

Actions
  • Price (EUR)282.00
  • Today's Change17.90 / 6.78%
  • Shares traded37.00
  • 1 Year change-23.27%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 17:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments854894763
Total Receivables, Net512507489
Total Inventory435415378
Prepaid expenses------
Other current assets, total136103112
Total current assets1,9361,9201,742
Property, plant & equipment, net1,5131,2631,127
Goodwill, net109107110
Intangibles, net151823
Long term investments210205208
Note receivable - long term------
Other long term assets213839
Total assets3,8303,6173,314
LIABILITIES
Accounts payable242215232
Accrued expenses179159195
Notes payable/short-term debt000
Current portion long-term debt/capital leases1342.2044
Other current liabilities, total116142122
Total current liabilities672519594
Total long term debt73207209
Total debt207209253
Deferred income tax13144.90
Minority interest------
Other liabilities, total191192171
Total liabilities949932978
SHAREHOLDERS EQUITY
Common stock191919
Additional paid-in capital120232249
Retained earnings (accumulated deficit)3,5232,9882,457
Treasury stock - common(638)(371)(230)
Unrealized gain (loss)2.301.601.50
Other equity, total(146)(185)(161)
Total equity2,8812,6852,335
Total liabilities & shareholders' equity3,8303,6173,314
Total common shares outstanding747474
Treasury shares - common primary issue1.801.201.10
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.